Grand View Research, Inc.が発刊した調査レポートによると、世界の羊膜市場の規模は2030年までに85億ドルに達し、予測期間中のCAGRは14.8％と予想されます。外傷や火傷の症例数の世界的な増加、手術、および羊膜ベースの製品がもたらすさまざまな利点に関する認識の高まりが、それらの需要を推進させる要因です。羊膜には痛みを軽減する特性があり、外傷や眼科でこれらの組織を用いた製品の採用が増える可能性があります。
また、幹細胞や再生医療の研究開発費の増加や手術件数の増加も、市場の成長を促す重要な要因です。世界市場は、眼科、皮膚、脳、頭頸部、泌尿生殖器、他の外科手術などにおける幅広い用途によって、市場潜在力を増す可能性があります。さらに、世界中で羊膜ベースの移植が増加することによって市場全体の成長が促進されると予想されます。また、医師だけでなく個人の間で製品の利点に関する意識が高まることによって、予測期間中の需要が高まると予想されます。
一方で、熟練した専門家の不足が市場の成長を妨げるでしょう。羊膜を用いた製品は、静脈、圧迫、糖尿病性足潰瘍、眼科、外科手術などのさまざまな領域の治療、および慢性創傷の管理に最も一般的に使用されています。さらに、幹細胞研究や再生医療の分野での研究が増えるにつれて、さまざまな研究機関や学術機関がこれらの製品を他の用途に使用しやすくするための研究に取り組んでいます。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Application
1.1.3. End Use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1.1. Commodity flow analysis (Model 1)
1.6.1.2. Approach 1: Commodity flow approach
1.6.1.3. Volume price analysis (Model 2)
1.6.1.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.2.3. End-Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Amniotic Membranes Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Rising research on stem cell biology and regenerative medicine
3.4.1.2. Increasing awareness towards benefits offered by amniotic membrane
3.4.1.3. Rise in the number of accident and trauma cases
3.4.2. Market restraint analysis
3.4.2.1. Lack of skilled professionals
3.4.2.2. Lack of standardized guidelines
3.5. Amniotic Membranes Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier product
3.5.1.2. Buyer product
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Amniotic Membranes: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Cryopreserved Amniotic Membrane
4.1.2. Dehydrated Amniotic Membrane
4.2. Product Market Share, 2021 & 2030
4.3. Segment Dashboard
4.4. Global Amniotic Membranes Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
4.5.1. Cryopreserved Amniotic Membrane
4.5.1.1. Market estimates and forecast 2017 to 2030 (USD Million)
4.5.2. Dehydrated Amniotic Membrane
4.5.2.1. Market estimates and forecast 2017 to 2030 (USD Million)
Chapter 5. Amniotic Membranes: Application Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Surgical Wounds
5.1.2. Ophthalmology
5.1.3. Others
5.2. Application Market Share, 2021 & 2030
5.3. Segment Dashboard
5.4. Global Amniotic Membranes Market by Application Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
5.5.1. Surgical Wounds
5.5.1.1. Market estimates and forecast 2017 to 2030 (USD million)
5.5.2. Ophthalmology
5.5.2.1. Market estimates and forecast 2017 to 2030 (USD Million)
5.5.3. Others
5.5.3.1. Market estimates and forecast 2017 to 2030 (USD Million)
Chapter 6. Amniotic Membranes: End-Use Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Hospitals
6.1.2. Ambulatory Surgical Centers
6.1.3. Specialty Clinics
6.1.4. Research and Academic Institutes
6.2. End Use Market Share, 2021 & 2030
6.3. Segment Dashboard
6.4. Global Amniotic Membranes Market by End-Use Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
6.5.1. Hospitals
6.5.1.1. Market estimates and forecast 2017 to 2030 (USD million)
6.5.2. Ambulatory Surgical Centers
6.5.2.1. Market estimates and forecast 2017 to 2030 (USD Million)
6.5.3. Specialty Clinics
6.5.3.1. Market estimates and forecast 2017 to 2030 (USD Million)
6.5.4. Research and Academic Institutes
6.5.4.1. Market estimates and forecast 2017 to 2030 (USD Million)
Chapter 7. Amniotic Membranes Market: Regional Estimates & Trend Analysis
7.1. Regional market share analysis, 2021 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Regional Market Share and Leading Players, 2020
7.4.1. North America
7.4.2. Europe
7.4.3. Asia Pacific
7.4.4. Latin America
7.4.5. Middle East and Africa
7.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East and Africa
7.6. Market Size, & Forecasts, Volume and Trend Analysis, 2017 to 2030
7.7. North America
7.7.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.7.2. U.S.
7.7.2.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.7.3. Canada
7.7.3.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.8. Europe
7.8.1. U.K.
7.8.1.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.8.2. Germany
7.8.2.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.8.3. France
7.8.3.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.8.4. Italy
7.8.4.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.8.5. Spain
7.8.5.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.9. Asia Pacific
7.9.1. China
7.9.1.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.9.2. Japan
7.9.2.1. Market estimates and forecast, 2017 - 2030 (Volume, Thousand)
7.9.3. India
7.9.3.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.9.4. Thailand
7.9.4.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.9.5. Australia
7.9.5.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.10. Latin America
7.10.1. Brazil
7.10.1.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.10.2. Mexico
7.10.2.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.10.3. Argentina
7.10.3.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.10.4. Colombia
7.10.4.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.11. MEA
7.11.1. Saudi Arabia
7.11.1.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.11.2. South Africa
7.11.2.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
7.11.3. UAE
7.11.3.1. Market estimates and forecast, 2017 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2021
8.3.4. Alliqua BioMedical Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Amnio Technology, LLC.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Applied Biologics LLC
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Human Regenerative Technologies, LLC
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. DermaSciences
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Katena Products, Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. MiMedx Group Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Skye Biologics, Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Amniox Medical Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Integra LifeSciences
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
